Compare Cincinnati Financial Corporation (CINF) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Crispr Therapeutics AG — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.58B), while Crispr Therapeutics AG trades at $53.9 (market cap $5.23B). The key difference: Cincinnati Financial Corporation is far larger — about 5.1× Crispr Therapeutics AG's market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CINF | CRSP | |
|---|---|---|
Market Cap | $26.58B | $5.23B |
Sector | Financials | Health |
52-Week High | $192.03 | $76.78 |
52-Week Low | $149.79 | $44.34 |
Enterprise Value | $25.71B | $3.65B |
Dividend Yield | 2.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
